Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled dose-escalation Phase 2 trial of rFVIIa (NovoSeven) for postoperative bleeding after cardiopulmonary bypass cardiac surgery
2004-000100-40Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postoperative hemorrhage comparing NovoSeven (rFVIIa) arm with Placebo arm (2 arms). Primary endpoint: Serious and critical adverse events. Started Jun 2004; status: completed.
02
Drugs
coagulation factor VIIa
03
Conditions
postoperative hemorrhage
Beyond the preview
Go deeper on 2004-000100-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000100-40.